Last 1.15 GBp
Change Today +0.025 / 2.22%
Volume 1.4M
VRP On Other Exchanges
As of 11:30 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

1.13 GBp
Previous Close
1.13 GBp
Day High
1.15 GBp
Day Low
1.13 GBp
52 Week High
10/30/13 - 5.64 GBp
52 Week Low
06/23/14 - 1.05 GBp
Market Cap
Average Volume 10 Days
-0.0068 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a biotechnology company, is engaged in the research, discovery, and development of therapeutic drugs in the United Kingdom and Canada. The company develops drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis (hay fever), and cough. Its lead drug compound include RPL554, a bronchodilator/anti-inflammatory drug that has completed Phase I and II clinical trials to treat asthma and COPD. The company is also developing VRP700, an anti-tussive drug, which has Phase II clinical trial for the treatment of cough, as well as novel anti-inflammatory polysaccharides (NAIPs) that in the basic research phase to treat respiratory and inflammatory diseases. The company is based in London, the United Kingdom.

10 Employees
Last Reported Date: 07/3/14

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.4K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 42.0K GBP
Compensation as of Fiscal Year 2013.

verona pharma plc (VRP) Key Developments

Verona Pharma plc, Annual General Meeting, Jun 12, 2014

Verona Pharma plc, Annual General Meeting, Jun 12, 2014., at 10:00 GMT Standard Time. Location: at the offices of SGH Martineau LLP, 5th Floor. Agenda: To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2013 and the report of the auditors thereon; to approve the directors' remuneration report for the year ended 31 December 2013; to consider reelection of directors; to re-appoint UHY Hacker Young LLP as auditors; to allot and make offers to allot relevant securities; and to consider the allotment of equity securities.

Verona Pharma plc Presents at BioEquity Europe 2014, May-22-2014 02:00 PM

Verona Pharma plc Presents at BioEquity Europe 2014, May-22-2014 02:00 PM. Venue: Hilton Amsterdam Hotel, Amsterdam, Netherlands.

Verona Pharma plc Reports Audited Group and Company Earnings Results for the Year Ended December 31, 2013

Verona Pharma plc reported audited group and company earnings results for the year ended December 31, 2013. For the period, the company reported operating loss of GBP 2,816,784 compared to GBP 2,585,349 a year ago. Loss before taxation was GBP 2,814,152 compared to GBP 2,565,172 a year ago. Loss for the year was GBP 2,524,752 compared to GBP 2,517,103 a year ago. Basic and diluted loss per ordinary share was 0.74 pence compared to 0.82 pence a year ago. Net cash outflow from operating activities was GBP 2,343,944 compared to GBP 2,573,609 a year ago. Purchase of plant and equipment was GBP 2,033 compared to GBP 46,594 a year ago. For the period, on a company basis, the company reported net cash outflow from operating activities of GBP 2,332,329 compared to GBP 2,561,282 a year ago. Purchase of plant and equipment was GBP 2,033 compared to GBP 46,594 a year ago. Operating loss was GBP 2,814,267 compared to GBP 2,582,534 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 1.15 GBp +0.025

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies

Industry Analysis


Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at